IN2014DN07410A - - Google Patents

Info

Publication number
IN2014DN07410A
IN2014DN07410A IN7410DEN2014A IN2014DN07410A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A IN 7410DEN2014 A IN7410DEN2014 A IN 7410DEN2014A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
inhibitor
prodrug
relates
pharmaceutical combination
Prior art date
Application number
Other languages
English (en)
Inventor
Ralph Tiedt
Alan Buckler
Fred Harbinski
Sneha Sanghavi
Douglas Jeffery
Christopher Wilson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN07410A publication Critical patent/IN2014DN07410A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN7410DEN2014 2012-04-03 2013-04-01 IN2014DN07410A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261619502P 2012-04-03 2012-04-03
PCT/US2013/034759 WO2013151913A1 (en) 2012-04-03 2013-04-01 Tyrosine kinase inhibitor combinations and their use

Publications (1)

Publication Number Publication Date
IN2014DN07410A true IN2014DN07410A (de) 2015-04-24

Family

ID=48184451

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7410DEN2014 IN2014DN07410A (de) 2012-04-03 2013-04-01

Country Status (11)

Country Link
US (1) US20150051210A1 (de)
EP (1) EP2833917A1 (de)
JP (1) JP2015512447A (de)
KR (1) KR20140146086A (de)
CN (1) CN104244982A (de)
AU (1) AU2013243737B2 (de)
CA (1) CA2866321A1 (de)
IN (1) IN2014DN07410A (de)
MX (1) MX2014011987A (de)
RU (1) RU2014143213A (de)
WO (1) WO2013151913A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39784B1 (fr) * 2014-03-26 2021-03-31 Astex Therapeutics Ltd Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
KR20170036037A (ko) * 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
AU2016237222B2 (en) 2015-03-25 2021-04-29 Eisai R&D Management Co., Ltd. Therapeutic agent for bile duct cancer
CA3001969C (en) 2015-12-17 2023-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005038537A1 (de) 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
CA2667428A1 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
ES2560435T3 (es) 2006-11-22 2016-02-19 Incyte Holdings Corporation Imidazotriazinas e imidazopirimidinas como inhibidores de la quinasa
JP4994044B2 (ja) * 2007-01-05 2012-08-08 シェブロンジャパン株式会社 潤滑油組成物
ES2529790T3 (es) * 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
MX2010011959A (es) * 2008-04-29 2010-11-30 Novartis Ag Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.
AU2009246263B2 (en) * 2008-05-14 2014-08-21 Amgen Inc. Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
CN103391773A (zh) * 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂

Also Published As

Publication number Publication date
MX2014011987A (es) 2014-11-10
CN104244982A (zh) 2014-12-24
EP2833917A1 (de) 2015-02-11
RU2014143213A (ru) 2016-05-27
KR20140146086A (ko) 2014-12-24
US20150051210A1 (en) 2015-02-19
AU2013243737B2 (en) 2016-06-30
JP2015512447A (ja) 2015-04-27
AU2013243737A1 (en) 2014-09-25
WO2013151913A1 (en) 2013-10-10
CA2866321A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
IN2015DN00598A (de)
IN2014DN10670A (de)
MX361499B (es) Baricitinib deuterado.
MA39749A (fr) Dérivés de pipéridine-dione
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
PH12015502091A1 (en) Cdc7 inhibitors
EP2980585A4 (de) Vitalfärbung
EP3019166A4 (de) Pharmazeutische zusammensetzungen zur behandlung von melanomen
MX2015008829A (es) Momelotinib deuterado.
MX366983B (es) Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen.
IN2014DN07996A (de)
EP3008651A4 (de) Geschäftsübergreifende lizenzierung für produkte von drittanbietern
IN2014DN11078A (de)
IN2014DN06738A (de)
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
MY165088A (en) Pharmaceutical compositions comprising alisporivir
NZ717192A (en) Anti-inflammatory tripeptides
EP3166405A4 (de) 3 '-substituierte-abscisinsäure-derivate
EP3025711A4 (de) Medikament zur vorbeugung oder behandlung von hypertonie
PH12016500809B1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
MX2015012610A (es) Pacritinib deuterizado.
EP3069326A4 (de) Modulare produktverkaufsanlage
MX2015001134A (es) Compuestos terapeuticos.
EP3016535A4 (de) Modulares aufprallschutzsystem für athletische bekleidung
HK40007630A (en) Aliphatic prolinamide derivatives